What is multikine?

What is multikine?

Multikine is an investigational immunotherapeutic agent being developed as a potential treatment for head and neck cancer, and cervical dysplasia or peri-anal warts in HIV/HPV (human immunodeficiency virus / and human papillomavirus) co-infected patients.

What does Cel Sci do?

CEL-SCI Corporation (NYSE American: CVM), a biotechnology company, is involved in the research and development of immunotherapy products for the treatment of cancer, autoimmune and infectious diseases. Use your immune system to fight disease.

Is CEL SCI a good buy?

CEL-SCI Corp (NYSE American:CVM) The 1 analysts offering 12-month price forecasts for CEL-SCI Corp have a median target of 17.00, with a high estimate of 17.00 and a low estimate of 17.00. The median estimate represents a +368.32% increase from the last price of 3.63.

Is CEL-SCI a good buy?

Why did Cel-Sci stock drop?

Cel-Sci was looking to show adding Multikine to standard of care causes at least a 10-percentage point improvement in overall survival, but the study fell short of that goal. The failure sent shares in Cel-Sci down 45%.

Will Cel-Sci stock go up?

The 1 analysts offering 12-month price forecasts for CEL-SCI Corp have a median target of 17.00, with a high estimate of 17.00 and a low estimate of 17.00. The median estimate represents a +461.98% increase from the last price of 3.03.

Why is CEL-SCI dropping?

CEL-SCI plummets 43% after phase 3 immunotherapy data misses primary endpoint. Shares of CEL-SCI Corp. (NYSE:CVM) have plummeted 43% after phase 3 data on its Multikine (leukocyte interleukin) immunotherapy candidate missed its primary endpoint for head and neck cancer.

Will Cel Sci stock go up?

Why did CVM go down?

07, 2019 6:13 PM CVM is down 2.4% postmarket after Stat News’ Adam Feuerstein posts a critical piece on the company’s disclosures about its immunotherapy Multikine. The company has “misled investors repeatedly” about the treatment, which is “still destined to fail.

Should I invest in CEL-SCI?

Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Cel-Sci Corp is ‘Hold’. Macroaxis provides Cel-Sci Corp buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CVM positions.

Is CEL-SCI a buy?

CEL-SCI Corp (NYSE American:CVM) The 1 analysts offering 12-month price forecasts for CEL-SCI Corp have a median target of 17.00, with a high estimate of 17.00 and a low estimate of 17.00. The median estimate represents a +279.46% increase from the last price of 4.48.

Will CVM stock recover?

Based on our forecasts, a long-term increase is expected, the “CVM” stock price prognosis for 2027-06-25 is 9.556 USD. With a 5-year investment, the revenue is expected to be around +112.36%. Your current $100 investment may be up to $212.36 in 2027. Get It Now!

Will CVM recover?

Based on our forecasts, a long-term increase is expected, the “CVM” stock price prognosis for 2027-05-26 is 11.026 USD. With a 5-year investment, the revenue is expected to be around +201.24%. Your current $100 investment may be up to $301.24 in 2027. Get It Now!

Is CVM stock a good buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for CEL-SCI Corporation stock to perform well in the short-term.

How high does CVM go?

CEL-SCI Corp (NYSE American:CVM) The 1 analysts offering 12-month price forecasts for CEL-SCI Corp have a median target of 17.00, with a high estimate of 17.00 and a low estimate of 17.00. The median estimate represents a +311.62% increase from the last price of 4.13.